Galectin Therapeutics (GALT) Stock Hits New Highs: Up 150% in a Month

Over the course of the past month or so, the Galectin Therapeutics (NASDAQ:GALT) stock has made considerable gains and the trend continued on Wednesday. Yesterday, the stock rallied by 23% to take its gains for the past month to as much as 150%.

Galectin Therapeutics (GALT) Stock Hits New Highs: Up 150% in a Month

One of the biggest triggers for the rally in the Galectin stock came about after the company announced that Dr. Ben Carson had been appointed as a special consultant to the company.

Related:  Weekly Growing Stock To Consider: Cellectar Biosciences (NASDAQ: CLRB)

It is a major development for the company considering Dr. Carson’s credentials. He is a globally renowned neurosurgeon. However, that is not all. Dr. Carson had also worked with the government and has served as the Secretary of the United States Department of Housing and Urban Development.

He is going to be involved with the development of the Galectin 3 inhibitor at the company. Considering the gains made by the company in recent times, it might be worthwhile for investors to keep an eye on the Galectin stock.

Jack Dawkins

Finance and Tech Contributor